You searched for "Emergency"

1867 results found

‘Phaco-plus’ procedures at forefront of modern glaucoma management

Glaucoma and cataract increasingly present as a ‘two-in-one’ surgical opportunity. In the UK, new modelling suggests ~1 million adults aged ≥40 may currently have glaucoma, with a projected rise to ~1.6 million by 2060 as the population ages and demographics...

Blinking blepharitis has a lot to answer for…

Never ignore the small things’…someone once said. There is no doubt blepharitis is one of the most common eye conditions encountered daily, but with the typical pressures of a busy outpatient department, the management of more obvious, sight-threatening conditions necessarily...

Video consultations after COVID-19

In the context of the COVID-19 pandemic, video consultations (VC) in eye care have been adopted in some regions and hospitals as a way of replacing some face to face ophthalmic consultations. I would like to use this column to...

Broadening horizons in ophthalmology: crafting a varied elective experience

The elective period for medical students is a unique opportunity to immerse oneself in a field of interest. For students interested in ophthalmology, this can offer a dedicated experience for what can otherwise be quite limited through undergraduate rotations. Alongside...

Identifying life-threatening uveal melanoma: A directed application of general-purpose AI

Uveal melanoma (UM) is a rare but aggressive eye cancer, affecting approximately six people per million annually [1]. Uveal melanoma arises in three locations: the choroid, ciliary body, and iris. As the most common primary intraocular malignancy in adults, UM...

The role of aspirin in the treatment of NAION: Benefits and controversies

Non-arteritic anterior ischaemic optic neuropathy (NAION) is the most common acute optic neuropathy in individuals over 50 with estimated prevalence of 2–10 per 100,000 people, characterised by sudden, unilateral vision loss due to ischaemic injury to the optic nerve head....

My Top Five: Emerging technologies revolutionising ophthalmology

Advancements in ophthalmology have significantly transformed eyecare practices. This article explores five emerging technologies that are revolutionising the field, from virtual reality (VR) surgical training to novel therapies for corneal conditions. These innovations are reshaping how eyecare professionals diagnose, treat...

Learnings and trends in the management of open-angle and angle-closure glaucoma

To be truly disruptive, newer technologies need to offer a quality of life benefit over medication to a broad population of glaucoma sufferers. Evidence and converging trends in medical and surgical management of glaucoma were explored in counterpoint discussions and...

Emerging developments in dry eye

An estimated 344 million people worldwide suffer from dry eye [1]. This chronic syndrome is characterised by a vicious cycle of tear film hyperosmolarity, tear instability and corneal stress, leading to increased friction, inflammation, ocular surface damage and decreased visual...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

Considerations in the management of retinal disorders

Vision research presentations and publications explore practice considerations in the management of AMD and diabetic retinopathy. Over the past two decades in Europe there has been a decreasing prevalence of age-related macular degeneration (AMD) and an improvement in visual acuity...

What's trending Jun/Jul 2020

Here in the UK, we’ve been in lockdown since 23 March 2020, with much of the rest of the world entering degrees of lockdown since February-March 2020. COVID-19 has dominated the headlines and social media, so without further ado, I...